Investing.com - Citizens重申对 Sana Biotechnology (NASDAQ:SANA) 股票的"市场跑赢大盘"评级,并维持8.00美元的目标价,较当前3.82美元的股价高出一倍以上。这家生物技术公司目前市值为10.2亿美元。

消息面上，Vir Biotechnology第四季度营收为6407万美元，同比增长417%，市场预期为4416万美元；每股亏损0.31美元，去年同期每股亏损0.76美元。此外，公司宣布VIR-5500的1期临床试验中取得积极结果，VIR-5500是一种用于治疗晚期转移性去势抵抗性前列腺癌的在研疗法。 (格隆汇) ...

Investing.com -- MAIA Biotechnology 股价在周二盘前交易中下跌29%至$1.47,此前这家药物开发商宣布以大幅折价进行3000万美元的公开发行。

在今日的股市交易中，Vir Biotechnology (VIR.US) 的股价表现引人注目，最高涨幅超过38%，触及10.29美元，创下逾一年以来的新高。这一涨幅的主要驱动力来自于公司发布的第四季度财报，其营收为6407万美元，同比大幅增长417%，超出市场预期的4416万美元。此外，每股亏损改善至0.31美元，相较于去年同期的0.76美元显著好转，显示出公司在财务上的积极变化。

Puma Biotechnology (NASDAQ:PBYI) reported fourth-quarter 2025 total revenue of $75.5 million, driven by NERLYNX product ...

Anbio Biotechnology continues pivoting toward better profitability metrics, prioritized high-margin orders over sales volume. Read more on NNNN stock here.

The United States has long led the global biomedical research and pharmaceutical development industry - but that leadership ...

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...

Experts discuss biotechnology's role in advancing personalized medicine at a VIT webinar, highlighting career opportunities ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor ...